---
title: "Simcere Pharmaceutical Forecasts Slight Increase in 2024 Profit"
description: "Simcere Pharmaceutical's attributable profit is seen to jump 0.4% to 4.6% to between 718 million yuan and 748 million yuan in 2024 from 715 million yuan in 2023, according to a Friday filing with the "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/229167347.md"
published_at: "2025-02-21T10:03:43.000Z"
---

# Simcere Pharmaceutical Forecasts Slight Increase in 2024 Profit

> Simcere Pharmaceutical's attributable profit is seen to jump 0.4% to 4.6% to between 718 million yuan and 748 million yuan in 2024 from 715 million yuan in 2023, according to a Friday filing with the Hong Kong Stock Exchange. Revenue is also forecast to inch up 0.2% to 0.6% to between 6.62 billion yuan and 6.65 billion yuan. The drug company plans to release fiscal 2024 results in late March.

Simcere Pharmaceutical's attributable profit is seen to jump 0.4% to 4.6% to between 718 million yuan and 748 million yuan in 2024 from 715 million yuan in 2023, according to a Friday filing with the Hong Kong Stock Exchange.

Revenue is also forecast to inch up 0.2% to 0.6% to between 6.62 billion yuan and 6.65 billion yuan.

The drug company plans to release fiscal 2024 results in late March.

### Related Stocks

- [02096.HK - SIMCERE PHARMA](https://longbridge.com/en/quote/02096.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 讀懂金銀銅：培風客陳大鵬帶你理解全球秩序重構下的資源品定價新機遇 | 3 月 15 日，原紫金礦業投資經理陳大鵬帶你拆解全球金屬定價新範式 | [Link](https://longbridge.com/en/news/276523437.md) |
| 財報説話：海外跨國企業如何看中國內需修復？ | 內需修復仍在進行中，科技進展和情緒消費是結構亮點。全球 30 家大型跨國企業的中國區業績顯示，45% 認為 4Q25 業績改善，33% 預期未來進一步改善。房地產拖累增長，但科技需求上升為傳統企業帶來新機遇。服務消費逆勢增長，金融、互聯網、 | [Link](https://longbridge.com/en/news/276837472.md) |
| 西部大行 “新班子” 再現變化，“內部人” 兼任關鍵崗位 | 重慶銀行再次調整高管，王偉列被聘為首席合規官，需經監管局核准。他長期在重慶銀行工作，現兼任首席風險官，顯示出該行高管頻繁變動的趨勢。過去一年，該行高管層經歷多次變更，包括劉建華、楊世銀等人的辭職及新任副行長的任命。 | [Link](https://longbridge.com/en/news/276882742.md) |
| SK 海力士將投資 150 億美元在韓國龍仁建設新設施 | 據聲明顯示，SK 海力士將在韓國龍仁建設新設施，投資 21.6 萬億韓元（約 150 億美元）。風險提示及免責條款 市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見 | [Link](https://longbridge.com/en/news/276864528.md) |
| 新政帶來哪些購房利好？對市場走勢有何影響？專家解讀上海樓市 “新七條” | 非滬籍社保滿 1 年即可購買外環內住房；公積金最高可貸 324 萬且落實 “認房不認貸”；特定首套暫免房產税。新政直擊職住平衡、宜居安居、剛需改善痛點，大幅降低買房與置換成本，促進住房消費需求積極釋放和供求關係平衡，鞏固當前樓市穩中向好的態 | [Link](https://longbridge.com/en/news/276862795.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.